-+ 0.00%
-+ 0.00%
-+ 0.00%

Minerva Neurosciences Unveils Roluperidone Phase 3 Trial Plans for Negative Symptoms of Schizophrenia

Reuters·02/03/2026 21:35:19

Please log in to view news